SFRP5 and metabolic dysfunction-associated steatotic liver disease: In this regard, further study to develop new anti-inflammatory strategies, such as SFRP5 enhancing action, may prevent NAFLD progression to NASH or even ameliorate NASH condition [39,40,41].